Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Helman Website

Lee J. Helman, M.D.

Selected Publications

1)  Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ.
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Oncogene. [Epub ahead of print], 2013.
[Journal]
2)  Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jahromi MS, Xekouki P, Szarek E, Walker R, Lasota J, Raffeld M, Klotzle B, Wang Z, Jones L, Zhu YJ, Wang Y, Waterfall J, O'Sullivan M, Bibikova M, Pacak K, Stratakis CA, Janeway KA, Schiffman JD, Fan J, Helman LJ, Meltzer PS.
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.
Cancer Discov. [Epub ahead of print], 2013.
[Journal]
3)  Grohar PJ, Helman LJ.
Prospects and challenges for the development of new therapies for Ewing sarcoma.
Pharmacol. Ther. 137: 216-24, 2013.
[Journal]
4)  Wiener L, Battles H, Zadeh S, Smith CJ, Helman LJ, Kim SY.
Gastrointestinal stromal tumor: psychosocial characteristics and considerations.
Support Care Cancer. 20: 1343-9, 2012.
[Journal]
5)  Schayek H, Bentov I, Jacob-Hirsch J, Yeung C, Khanna C, Helman LJ, Plymate SR, Werner H.
Global Methylation Analysis Identifies PITX2 as an Upstream Regulator of the Androgen Receptor and IGF-I Receptor Genes in Prostate Cancer.
Horm. Metab. Res. 44: 511-9, 2012.
[Journal]
6)  Wan X, Yeung C, Kim SY, Dolan JG, Ngo VN, Burkett S, Khan J, Staudt LM, Helman LJ.
Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma.
Cancer Res. 72: 5889-99, 2012.
[Journal]
7)  Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS, Helman LJ.
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Oncologist. 17: 321, 2012.
[Journal]
8)  Teicher BA, Linehan WM, Helman LJ.
Targeting cancer metabolism.
Clin. Cancer Res. 18: 5537-45, 2012.
[Journal]
9)  Arnaldez FI, Helman LJ.
Targeting the insulin growth factor receptor 1.
Hematol. Oncol. Clin. North Am. 26: 527-42, vii-viii, 2012.
[Journal]
10)  Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R.
The first European interdisciplinary ewing sarcoma research summit.
Front Oncol. 2: 54, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/11/2013.